CN116171324A - 用于治疗和预防冠状病毒感染的方法和组合物 - Google Patents

用于治疗和预防冠状病毒感染的方法和组合物 Download PDF

Info

Publication number
CN116171324A
CN116171324A CN202180058122.4A CN202180058122A CN116171324A CN 116171324 A CN116171324 A CN 116171324A CN 202180058122 A CN202180058122 A CN 202180058122A CN 116171324 A CN116171324 A CN 116171324A
Authority
CN
China
Prior art keywords
ace2
cov
coronavirus
protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180058122.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·托尔基亚
G·J·弗里曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CN116171324A publication Critical patent/CN116171324A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180058122.4A 2020-07-20 2021-07-20 用于治疗和预防冠状病毒感染的方法和组合物 Pending CN116171324A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063053817P 2020-07-20 2020-07-20
US63/053,817 2020-07-20
US202163150686P 2021-02-18 2021-02-18
US63/150,686 2021-02-18
PCT/US2021/042372 WO2022020353A2 (en) 2020-07-20 2021-07-20 Methods and compositions for treatment and prevention of coronavirus infection

Publications (1)

Publication Number Publication Date
CN116171324A true CN116171324A (zh) 2023-05-26

Family

ID=77301019

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180058122.4A Pending CN116171324A (zh) 2020-07-20 2021-07-20 用于治疗和预防冠状病毒感染的方法和组合物

Country Status (8)

Country Link
US (1) US20230272359A1 (https=)
EP (1) EP4182458A2 (https=)
JP (1) JP2023535695A (https=)
KR (1) KR20230058045A (https=)
CN (1) CN116171324A (https=)
AU (1) AU2021312238A1 (https=)
CA (1) CA3189732A1 (https=)
WO (1) WO2022020353A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
EP4132478A1 (en) 2020-04-09 2023-02-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
CA3185230A1 (en) * 2020-07-06 2022-01-13 Shengjiang Liu Catalysis deactivated angiotensin-converting enzyme 2 (ace2) variants and their uses
US20230374153A1 (en) * 2022-04-13 2023-11-23 Paradigm Immunoterapeutics, Inc. METHODS OF PREVENTING OR TREATING INFECTION BY RESPIRATORY VIRUSES INCLUDING SARS-CoV-2
CN119265271B (zh) * 2024-12-09 2025-04-22 上海益诺思生物技术股份有限公司 一种评价ade效应的系统及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080159962A1 (en) * 2005-05-19 2008-07-03 Imba-Institute Fur Molekulare Biotechnologie Gmbh Use of Inhibitors of the Renin-Angiotensin System for the Treatment of Lung Injuries
CN104582736A (zh) * 2012-06-21 2015-04-29 印第安纳大学研究及科技有限公司 Fc效应子功能改变的肠降血糖素受体配体多肽Fc区融合多肽和缀合物
CN105949313A (zh) * 2011-03-29 2016-09-21 罗切格利卡特公司 抗体Fc变体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US6174530B1 (en) 1993-05-05 2001-01-16 Gryphon Sciences Homogeneous polyoxime compositions and their preparation by parallel assembly
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
WO2000070032A1 (en) * 1999-05-13 2000-11-23 Zymogenetics, Inc. Zace2: a human metalloenzyme
US20040102369A1 (en) * 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US20070185044A1 (en) * 2005-03-08 2007-08-09 Dobie Kenneth W Modulation of ace2 expression
HK1214652A1 (zh) * 2013-03-13 2016-07-29 克里蒂科斯有限责任公司 用於检测胰腺癌的方法和组合物
CN107207594B (zh) * 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
WO2021183404A1 (en) * 2020-03-07 2021-09-16 Planet Biotechnology, Inc. Ace2-fc fusion proteins for sars-cov-2 mitigation
CN113444710A (zh) * 2020-03-25 2021-09-28 上海英脉德医疗科技有限公司 ACE2-Fc融合蛋白及其用途
WO2021202427A2 (en) * 2020-03-29 2021-10-07 R-Pharm Overseas, Inc. Ace2-derived composition and use thereof
JP2023526540A (ja) * 2020-05-22 2023-06-21 フォーマイコン アーゲー Ａｃｅ２融合タンパク質及びその使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080159962A1 (en) * 2005-05-19 2008-07-03 Imba-Institute Fur Molekulare Biotechnologie Gmbh Use of Inhibitors of the Renin-Angiotensin System for the Treatment of Lung Injuries
CN105949313A (zh) * 2011-03-29 2016-09-21 罗切格利卡特公司 抗体Fc变体
CN104582736A (zh) * 2012-06-21 2015-04-29 印第安纳大学研究及科技有限公司 Fc效应子功能改变的肠降血糖素受体配体多肽Fc区融合多肽和缀合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAOKI IWANAGA 等: "Novel ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV2", BIORXIV, 15 June 2020 (2020-06-15) *
ROBERT L KRUSE: "Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China", F1000RESEARCH, vol. 9, no. 72, 31 January 2020 (2020-01-31), pages 1 - 15 *

Also Published As

Publication number Publication date
JP2023535695A (ja) 2023-08-21
US20230272359A1 (en) 2023-08-31
WO2022020353A3 (en) 2022-03-10
WO2022020353A2 (en) 2022-01-27
EP4182458A2 (en) 2023-05-24
CA3189732A1 (en) 2022-01-27
AU2021312238A1 (en) 2023-02-23
KR20230058045A (ko) 2023-05-02

Similar Documents

Publication Publication Date Title
CN116171324A (zh) 用于治疗和预防冠状病毒感染的方法和组合物
US20230218743A1 (en) Peptide Therapeutics Against SARS-COV-2 Spike Protein
IL295310A (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2021205184A1 (en) Polypeptide
CN118679181B (zh) 乙型冠状病毒广谱中和抗体及其应用
Naidoo et al. The potential of nanobodies for COVID-19 diagnostics and therapeutics
CN116096745A (zh) 抗sars-cov-2纤突糖蛋白抗体和抗原结合片段
CN118994380A (zh) 抗新型冠状病毒抗体及其应用
Wines et al. Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
KR20230141853A (ko) 사베코바이러스 결합제
WO2021195385A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
US20230374153A1 (en) METHODS OF PREVENTING OR TREATING INFECTION BY RESPIRATORY VIRUSES INCLUDING SARS-CoV-2
WO2021021830A1 (en) Antibodies to candida and uses thereof
US20230310584A1 (en) Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigen
CN114891075A (zh) 一种对新冠病毒s蛋白rbmfp结构域具有结合亲和力的多肽及其应用
CN116693671A (zh) 新型冠状病毒中和性抗体及其制备方法与用途
Schepens et al. Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents
US20230181714A1 (en) Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
EP4335870A1 (en) Peptide therapeutics against sars-cov-2 spike protein
WO2022026807A2 (en) Antibodies targeting sars-cov-2 and uses thereof
US20250304659A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 1 (SARS-CoV-1)
WO2024015760A2 (en) Human monoclonal antibodies to omicron variant of severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
Gach et al. Phagocytic Clearance of SARS-CoV-2 Nucleocapsid-and RNA-Containing Immune Complexes Drives Inflammatory Cytokine Production and Endothelial Dysfunction
WO2005007671A2 (en) Compositions and methods for treating sars
EP4720675A2 (en) Human monoclonal antibodies for human parainfluenza virus type 3

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination